Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial

Novo Nordisk shares plunged on Friday, erasing more than $30 billion in market value after the Danish drugmaker said a late-stage experimental drug failed in a large study, drawing criticism from analysts who said the firm missed an opportunity to expand beyond its weight-loss offerings. READ MORE: https://www.forbes.com/sites/tylerroush/2026/07/31/novo-nordisk-wipes-out-30-billion-in-market-value-after-failed-heart-drug-trial/ Stay Connected Forbes Breaking News on X: https://x.com/ForbesTVNews Forbes Breaking News on TikTok: https://www.tiktok.com/@forbestvnews More From Forbes: http://forbes.com